title: Quantitative measurement of full-length and C-terminal proteolyzed RBP4 in serum of normal and insulin-resistant humans using a novel mass spectrometry immunoassay.
abstract: Serum retinol-binding protein 4 (RBP4) levels are increased in insulin-resistant humans and correlate with severity of insulin resistance in metabolic syndrome. Quantitative Western blotting (qWestern) has been the most accurate method for serum RBP4 measurements, but qWestern is technically complex and labor intensive. The lack of a reliable, high-throughput method for RBP4 measurements has resulted in variability in findings in insulin-resistant humans. Many commonly used ELISAs have limited dynamic range. Neither the current ELISAs nor qWestern distinguish among full-length and carboxyl terminus proteolyzed forms of circulating RBP4 that are altered in different medical conditions. Here, we report the development of a novel quantitative mass spectrometry immunoaffinity assay (qMSIA) to measure full-length and proteolyzed forms of RBP4. qMSIA and qWestern of RBP4 were performed in identical serum aliquots from insulin-sensitive/normoglycemic or insulin-resistant humans with impaired glucose tolerance or type 2 diabetes. Total RBP4 qMSIA measurements were highly similar to qWestern and correlated equally well with clinical severity of insulin resistance (assessed by clamp glucose disposal rate, r = -0.74), hemoglobin A1c (r = 0.63), triglyceride/high-density lipoprotein (r = 0.55), waist/hip (r = 0.61), and systolic blood pressure (r = 0.53, all P < 0.001). Proteolyzed forms of RBP4 accounted for up to 50% of total RBP4 in insulin-resistant subjects, and des(Leu)-RBP4 (cleavage of last leucine) correlated highly with insulin resistance (assessed by glucose disposal rate, r = -0.69). In multiple regression analysis, insulin resistance but not glomerular filtration rate was the strongest, independent predictor of serum RBP4 levels. Thus, qMSIA provides a novel tool for accurately measuring serum RBP4 levels as a biomarker for severity of insulin resistance and risk for type 2 diabetes and metabolic syndrome.
authors.affiliation: Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center, CLS 747, 330 Brookline Avenue, Boston, Massachusetts 02215, USA.
authors.forename: Qin
authors.initials: Q
authors.lastname: Yang
authors.forename: Iratxe
authors.initials: I
authors.lastname: Eskurza
authors.forename: Urban A
authors.initials: UA
authors.lastname: Kiernan
authors.forename: David A
authors.initials: DA
authors.lastname: Phillips
authors.forename: Matthias
authors.initials: M
authors.lastname: Blüher
authors.forename: Timothy E
authors.initials: TE
authors.lastname: Graham
authors.forename: Barbara B
authors.initials: BB
authors.lastname: Kahn
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000097:blood; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005260:Female; D005951:Glucose Tolerance Test; D006801:Humans; D007118:Immunoassay / Q000379:methods*; D007328:Insulin / Q000737:chemistry*; D007333:Insulin Resistance; D008297:Male; D013058:Mass Spectrometry / Q000379:methods; D024821:Metabolic Syndrome / Q000097:blood; D018408:Patch-Clamp Techniques; D017434:Protein Structure, Tertiary; D059748:Proteolysis; D015203:Reproducibility of Results; D054839:Retinol-Binding Proteins, Plasma / Q000378:metabolism*
chemical_list: D007328:Insulin; C101326:RBP4 protein, human; D054839:Retinol-Binding Proteins, Plasma